Follow Us
© 2026 Arizent. All rights reserved.
I have a coworker — who shall remain nameless — who’s quite fond of celebrating half-birthdays. Until I met him/her, I’d never even heard of them. But apparently, it’s the date six months after your actual birthday.
Absurd, I know. Which is why he/she shall remain nameless.
For reprint and licensing requests for this article, click here.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
The 2026 Excellence in Benefits winners are using AI to streamline operations and efficiently address employee concerns, but human judgment and empathy remain paramount.
As benefit decisions get finalized, childcare offerings may be more within reach than companies think.
Metabolism-management drugs and hormone therapy are growing in popularity, but women need expert clinical oversight in conjunction with medication access.
To truly flip the script on metabolic disease, benefit leaders must build a cost-efficient, supportive plan for employees and their business.
